Breaking News for May 3, 2004 issue
FDA Grants Tovorafenib Approval to Treat Relapsed or Refractory Pediatric Low-Grade Glioma
The approval for tovorafenib (Ojemda) was based on data from the phase 2 FIREFLY-1 trial, in which the therapy demonstrated an overall repose rate of 67%.
Is E-Prescribing the Future of Veterinary Medicine?
Wendy Crouse, DVM, an independent house call veterinarian with Heal House Call Veterinarian, sat down with Drug Topics to discuss how the adoption of e-prescribing has transformed her practice.
FDA Issues CRL for Epidermolysis Bullosa Gene Therapy
Abeona Therapeutics’ pz-cel is an investigational autologous, COL7A1 gene-corrected epidermal sheet therapy for the treatment of recessive dystrophic epidermolysis bullosa.
The Importance of Continuing Education in Pharmacy Compounding
Kevin Hope, RPh, senior director of pharmacy education at Pharmcon, joined Drug Topics to discuss pharmacy compounding from the new USP changes and the importance of education around compounding best practices.
Therapeutic Relationship Plays Key Role in Psychedelic Treatment
A higher patient-rated therapeutic alliance was associated with improvements in depression outcomes up to 1 year after treatment.
Weekend ICYMI: April 15 to April 19
In case you missed it, this week we had news about potential pharmacy unions, states' regulation of PBMs, rising insulin costs, and more.
